Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a biotechnology company focused on allogeneic CAR T (AlloCAR T™) products for cancer, announced its participation in the Jefferies Cell and Genetic Medicine Summit on September 30, 2022, at 6:30 AM Pacific Time. Management will present insights about its pipeline of 'off-the-shelf' CAR T cell candidates aimed at improving availability and scalability of cell therapy. A live webcast will be available on the company’s website, with a replay accessible for 30 days afterwards.
- Participation in the Jefferies Cell and Genetic Medicine Summit could enhance visibility and investor interest.
- Development of 'off-the-shelf' CAR T products may provide competitive advantage in the biotechnology sector.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 6:30AM Pacific Time/9:30AM Eastern Time.
The webcast will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T products for cancer and the potential benefits of AlloCAR T. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 8-K filed on September 21, 2022 and Form 10-Q for the quarter ended June 30, 2022. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
FAQ
What is Allogene Therapeutics planning to present at the Jefferies Cell and Genetic Medicine Summit?
When will the Allogene Therapeutics presentation at the summit take place?
Where can I watch the Allogene Therapeutics presentation?
How long will the replay of the Allogene Therapeutics summit presentation be available?
What is the goal of Allogene's CAR T cell products?
